Pretraga

Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1242275

Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)

(European Registry on Helicobacter pylori Management Hp-EuReg Investigators) Nyssen, Olga P.; Vaira, Dino; Perez Aisa, Angeles; Rodrigo, Luis; Castro-Fernandez, Manuel; Jonaitis, Laimas; Tepes, Bojan; Vologzhanina, Liudmila; Caldas, Maria; Lanas, Angel et al.
Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg) // Clinical gastroenterology and hepatology, 20 (2022), 10; 2243-2257 doi:10.1016/j.cgh.2021.12.025 (međunarodna recenzija, članak, znanstveni)

CROSBI ID: 1242275 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)

Autori
Nyssen, Olga P. ; Vaira, Dino ; Perez Aisa, Angeles ; Rodrigo, Luis ; Castro-Fernandez, Manuel ; Jonaitis, Laimas ; Tepes, Bojan ; Vologzhanina, Liudmila ; Caldas, Maria ; Lanas, Angel ; Lucendo, Alfredo J ; Bujanda, Luis ; Ortuno, Juan ; Barrio, Jesus ; Huguet, Jose M ; Voynovan, Irina ; Lasala, Jorge Perez ; Sarsenbaeva, Aiman Silkanovna ; Fernandez- Salazar, Luis ; Molina-Infante, Javier ; Jurecic, Natasa Brglez ; Areia, Miguel ; Gasbarrini, Antonio ; Kupcinskas, Juozas ; Bordin, Dmitry ; Marcos-Pinto, Ricardo ; Lerang, Frode ; Leja, Marcis ; Buzas, Gyorgy M. ; Niv, Yaron ; Rokkas, Theodore ; Phull, Perminder ; Smith, Sinead ; Shvets, Oleg ; Venerito, Marino ; Milivojevic, Vladimir ; Simsek, Ilkay ; Lamy, Vincent ; Bytzer, Peter ; Boyanova, Lyudmila ; Kunovsky, Lumir ; Beglinger, Christoph ; Doulberis, Michael ; Marlicz, Wojciech ; Goldis, Adrian ; Tonkić, Ante ; Capelle, Lisette ; Puig, Ignasi ; Megraud, Francis ; O'Morain, Colm ; Gisbert, Javier P.

Kolaboracija
European Registry on Helicobacter pylori Management Hp-EuReg Investigators

Izvornik
Clinical gastroenterology and hepatology (1542-3565) 20 (2022), 10; 2243-2257

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Bismuth ; Helicobacter pylori ; Clarithromycin ; Levofloxacin ; Rescue

Sažetak
BACKGROUND & AIMS: After a first Helicobacter pylori eradication attempt, approximately 20% of patients will remain infected. The aim of the current study was to assess the effectiveness and safety of second-line empiric treatment in Europe.METHODS: This international, multicenter, prospective, non-interventional registry aimed to evaluate the decisions and outcomes of H pylori management by European gastroenterologists. All infected adult cases with a previous eradication treatment attempt were registered with the Spanish Association of Gastroenterology-Research Electronic Data Capture until February 2021. Patients allergic to penicillin and those who received susceptibility-guided therapy were excluded. Data monitoring was performed to ensure data quality.RESULTS: Overall, 5055 patients received empiric second-line treatment. Triple therapy with amoxicillin and levofloxacin was prescribed most commonly (33%). The overall effectiveness was 82% by modified intention-to- treat analysis and 83% in the per-protocol population. After failure of first-line clarithromycin-containing treatment, optimal eradication (> ; 90%) was obtained with moxifloxacin-containing triple therapy or levofloxacin-containing quadruple therapy (with bismuth). In patients receiving triple therapy containing levofloxacin or moxifloxacin, and levofloxacin-bismuth quadruple treatment, cure rates were optimized with 14-day regimens using high doses of proton pump inhibitors. However, 3- in-1 single capsule or levofloxacin-bismuth quadruple therapy produced reliable eradication rates regardless of proton pump inhibitor dose, duration of therapy, or previous first-line treatment. The overall incidence of adverse events was 28%, and most (85%) were mild. Three patients developed serious adverse events (0.3%) requiring hospitalization.CONCLUSIONS: Empiric second-line regimens including 14-day quinolone triple therapies, 14-day levofloxacin-bismuth quadruple therapy, 14-day tetracycline-bismuth classic quadruple therapy, and 10-day bismuth quadruple therapy (as a single capsule) provided optimal effectiveness. However, many other second-line treatments evaluated reported low eradication rates. ClincialTrials.gov number: NCT02328131.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA

Ustanove:
Medicinski fakultet, Split

Profili:

Avatar Url Ante Tonkić (autor)

Poveznice na cjeloviti tekst rada:

doi www.sciencedirect.com

Citiraj ovu publikaciju:

(European Registry on Helicobacter pylori Management Hp-EuReg Investigators) Nyssen, Olga P.; Vaira, Dino; Perez Aisa, Angeles; Rodrigo, Luis; Castro-Fernandez, Manuel; Jonaitis, Laimas; Tepes, Bojan; Vologzhanina, Liudmila; Caldas, Maria; Lanas, Angel et al.
Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg) // Clinical gastroenterology and hepatology, 20 (2022), 10; 2243-2257 doi:10.1016/j.cgh.2021.12.025 (međunarodna recenzija, članak, znanstveni)
(European Registry on Helicobacter pylori Management Hp-EuReg Investigators) (European Registry on Helicobacter pylori Management Hp-EuReg Investigators) Nyssen, O., Vaira, D., Perez Aisa, A., Rodrigo, L., Castro-Fernandez, M., Jonaitis, L., Tepes, B., Vologzhanina, L., Caldas, M. & Lanas, A. (2022) Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg). Clinical gastroenterology and hepatology, 20 (10), 2243-2257 doi:10.1016/j.cgh.2021.12.025.
@article{article, author = {Nyssen, Olga P. and Vaira, Dino and Perez Aisa, Angeles and Rodrigo, Luis and Castro-Fernandez, Manuel and Jonaitis, Laimas and Tepes, Bojan and Vologzhanina, Liudmila and Caldas, Maria and Lanas, Angel and Lucendo, Alfredo J and Bujanda, Luis and Ortuno, Juan and Barrio, Jesus and Huguet, Jose M and Voynovan, Irina and Lasala, Jorge Perez and Sarsenbaeva, Aiman Silkanovna and Fernandez- Salazar, Luis and Molina-Infante, Javier and Jurecic, Natasa Brglez and Areia, Miguel and Gasbarrini, Antonio and Kupcinskas, Juozas and Bordin, Dmitry and Marcos-Pinto, Ricardo and Lerang, Frode and Leja, Marcis and Buzas, Gyorgy M. and Niv, Yaron and Rokkas, Theodore and Phull, Perminder and Smith, Sinead and Shvets, Oleg and Venerito, Marino and Milivojevic, Vladimir and Simsek, Ilkay and Lamy, Vincent and Bytzer, Peter and Boyanova, Lyudmila and Kunovsky, Lumir and Beglinger, Christoph and Doulberis, Michael and Marlicz, Wojciech and Goldis, Adrian and Tonki\'{c}, Ante and Capelle, Lisette and Puig, Ignasi and Megraud, Francis and O'Morain, Colm and Gisbert, Javier P.}, year = {2022}, pages = {2243-2257}, DOI = {10.1016/j.cgh.2021.12.025}, keywords = {Bismuth, Helicobacter pylori, Clarithromycin, Levofloxacin, Rescue}, journal = {Clinical gastroenterology and hepatology}, doi = {10.1016/j.cgh.2021.12.025}, volume = {20}, number = {10}, issn = {1542-3565}, title = {Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)}, keyword = {Bismuth, Helicobacter pylori, Clarithromycin, Levofloxacin, Rescue} }
@article{article, author = {Nyssen, Olga P. and Vaira, Dino and Perez Aisa, Angeles and Rodrigo, Luis and Castro-Fernandez, Manuel and Jonaitis, Laimas and Tepes, Bojan and Vologzhanina, Liudmila and Caldas, Maria and Lanas, Angel and Lucendo, Alfredo J and Bujanda, Luis and Ortuno, Juan and Barrio, Jesus and Huguet, Jose M and Voynovan, Irina and Lasala, Jorge Perez and Sarsenbaeva, Aiman Silkanovna and Fernandez- Salazar, Luis and Molina-Infante, Javier and Jurecic, Natasa Brglez and Areia, Miguel and Gasbarrini, Antonio and Kupcinskas, Juozas and Bordin, Dmitry and Marcos-Pinto, Ricardo and Lerang, Frode and Leja, Marcis and Buzas, Gyorgy M. and Niv, Yaron and Rokkas, Theodore and Phull, Perminder and Smith, Sinead and Shvets, Oleg and Venerito, Marino and Milivojevic, Vladimir and Simsek, Ilkay and Lamy, Vincent and Bytzer, Peter and Boyanova, Lyudmila and Kunovsky, Lumir and Beglinger, Christoph and Doulberis, Michael and Marlicz, Wojciech and Goldis, Adrian and Tonki\'{c}, Ante and Capelle, Lisette and Puig, Ignasi and Megraud, Francis and O'Morain, Colm and Gisbert, Javier P.}, year = {2022}, pages = {2243-2257}, DOI = {10.1016/j.cgh.2021.12.025}, keywords = {Bismuth, Helicobacter pylori, Clarithromycin, Levofloxacin, Rescue}, journal = {Clinical gastroenterology and hepatology}, doi = {10.1016/j.cgh.2021.12.025}, volume = {20}, number = {10}, issn = {1542-3565}, title = {Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)}, keyword = {Bismuth, Helicobacter pylori, Clarithromycin, Levofloxacin, Rescue} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE

Citati:

    Altmetrijski pokazatelji:


    Podijeli:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font
    CROSBI koristi kolačiće (cookies) kako bi poboljšao funkcionalnost stranice.